711 related articles for article (PubMed ID: 29929399)
21. The association between non-alcoholic fatty liver disease and atrial fibrillation: A meta-analysis.
Wijarnpreecha K; Boonpheng B; Thongprayoon C; Jaruvongvanich V; Ungprasert P
Clin Res Hepatol Gastroenterol; 2017 Oct; 41(5):525-532. PubMed ID: 28866089
[TBL] [Abstract][Full Text] [Related]
22. Non-alcoholic fatty liver disease is associated with an increased incidence of atrial fibrillation in patients with type 2 diabetes.
Targher G; Valbusa F; Bonapace S; Bertolini L; Zenari L; Rodella S; Zoppini G; Mantovani W; Barbieri E; Byrne CD
PLoS One; 2013; 8(2):e57183. PubMed ID: 23451184
[TBL] [Abstract][Full Text] [Related]
23. Risk of cardiovascular events in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis.
Alon L; Corica B; Raparelli V; Cangemi R; Basili S; Proietti M; Romiti GF
Eur J Prev Cardiol; 2022 May; 29(6):938-946. PubMed ID: 34939092
[TBL] [Abstract][Full Text] [Related]
24. Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Implications for Liver Transplantation.
Younossi ZM; Marchesini G; Pinto-Cortez H; Petta S
Transplantation; 2019 Jan; 103(1):22-27. PubMed ID: 30335697
[TBL] [Abstract][Full Text] [Related]
25. Not only type 2 diabetes but also prediabetes is associated with portal inflammation and fibrosis in patients with non-alcoholic fatty liver disease.
Yilmaz Y; Senates E; Yesil A; Ergelen R; Colak Y
J Diabetes Complications; 2014; 28(3):328-31. PubMed ID: 24602757
[TBL] [Abstract][Full Text] [Related]
26. Non-alcoholic fatty liver disease.
Powell EE; Wong VW; Rinella M
Lancet; 2021 Jun; 397(10290):2212-2224. PubMed ID: 33894145
[TBL] [Abstract][Full Text] [Related]
27. Prevalence and staging of non-alcoholic fatty liver disease among patients with heart failure with preserved ejection fraction.
Miller A; McNamara J; Hummel SL; Konerman MC; Tincopa MA
Sci Rep; 2020 Jul; 10(1):12440. PubMed ID: 32709942
[TBL] [Abstract][Full Text] [Related]
28. Risk factors for biopsy-proven advanced non-alcoholic fatty liver disease in the Veterans Health Administration.
Patel YA; Gifford EJ; Glass LM; McNeil R; Turner MJ; Han B; Provenzale D; Choi SS; Moylan CA; Hunt CM
Aliment Pharmacol Ther; 2018 Jan; 47(2):268-278. PubMed ID: 29115682
[TBL] [Abstract][Full Text] [Related]
29. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease.
Perumpail BJ; Khan MA; Yoo ER; Cholankeril G; Kim D; Ahmed A
World J Gastroenterol; 2017 Dec; 23(47):8263-8276. PubMed ID: 29307986
[TBL] [Abstract][Full Text] [Related]
30. Screening for non-alcoholic fatty liver disease using liver stiffness measurement and its association with chronic kidney disease and cardiovascular complications in patients with type 2 diabetes.
Mantovani A; Turino T; Lando MG; Gjini K; Byrne CD; Zusi C; Ravaioli F; Colecchia A; Maffeis C; Salvagno G; Lippi G; Bonora E; Targher G
Diabetes Metab; 2020 Sep; 46(4):296-303. PubMed ID: 31786361
[TBL] [Abstract][Full Text] [Related]
31. The Utility of Noninvasive Scores in Assessing the Prevalence of Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in Type 2 Diabetic Patients.
Singh A; Le P; Peerzada MM; Lopez R; Alkhouri N
J Clin Gastroenterol; 2018 Mar; 52(3):268-272. PubMed ID: 28787358
[TBL] [Abstract][Full Text] [Related]
32. Does nonalcoholic fatty liver disease cause cardiovascular disease? Current knowledge and gaps.
Santos RD; Valenti L; Romeo S
Atherosclerosis; 2019 Mar; 282():110-120. PubMed ID: 30731283
[TBL] [Abstract][Full Text] [Related]
33. Advanced fibrosis is associated with incident cardiovascular disease in patients with non-alcoholic fatty liver disease.
Henson JB; Simon TG; Kaplan A; Osganian S; Masia R; Corey KE
Aliment Pharmacol Ther; 2020 Apr; 51(7):728-736. PubMed ID: 32043602
[TBL] [Abstract][Full Text] [Related]
34. Non-alcoholic fatty liver disease: A growing public health problem in Turkey.
Kaya E; Yılmaz Y
Turk J Gastroenterol; 2019 Oct; 30(10):865-871. PubMed ID: 31258135
[TBL] [Abstract][Full Text] [Related]
35. Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV.
Lonardo A; Ballestri S; Guaraldi G; Nascimbeni F; Romagnoli D; Zona S; Targher G
World J Gastroenterol; 2016 Nov; 22(44):9674-9693. PubMed ID: 27956792
[TBL] [Abstract][Full Text] [Related]
36. Medications in type-2 diabetics and their association with liver fibrosis.
Siddiqui MT; Amin H; Garg R; Chadalavada P; Al-Yaman W; Lopez R; Singh A
World J Gastroenterol; 2020 Jun; 26(23):3249-3259. PubMed ID: 32684739
[TBL] [Abstract][Full Text] [Related]
37. Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.
Kabbany MN; Conjeevaram Selvakumar PK; Watt K; Lopez R; Akras Z; Zein N; Carey W; Alkhouri N
Am J Gastroenterol; 2017 Apr; 112(4):581-587. PubMed ID: 28195177
[TBL] [Abstract][Full Text] [Related]
38. The monocyte-to-high-density lipoprotein ratio is associated with the occurrence of atrial fibrillation among NAFLD patients: A propensity-matched analysis.
Wang L; Zhang Y; Yu B; Zhao J; Zhang W; Fan H; Ren Z; Liang B
Front Endocrinol (Lausanne); 2023; 14():1127425. PubMed ID: 37056665
[TBL] [Abstract][Full Text] [Related]
39. Prevalence and Profile of Fibrosis in Diabetic Patients with Non-alcoholic Fatty Liver Disease and the Associated Factors.
Prasetya IB; Hasan I; Wisnu W; Rumende CM
Acta Med Indones; 2017 Apr; 49(2):91-98. PubMed ID: 28790222
[TBL] [Abstract][Full Text] [Related]
40. Relations of Liver Fat With Prevalent and Incident Atrial Fibrillation in the Framingham Heart Study.
Long MT; Yin X; Larson MG; Ellinor PT; Lubitz SA; McManus DD; Magnani JW; Staerk L; Ko D; Helm RH; Hoffmann U; Chung RT; Benjamin EJ
J Am Heart Assoc; 2017 May; 6(5):. PubMed ID: 28465298
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
